Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan E Temel

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
Cell Reports|January 21, 2015
The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol BalanceManya Warrier, Diana M Shih, Amy C Burrows, et al.
Nature Biomedical Engineering|April 3, 2019
Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primatesMarnix Lameijer, Tina Binderup, Mandy M T van Leent, et al.
Nature Biomedical Engineering|April 25, 2019
Author Correction: Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primatesMarnix Lameijer, Tina Binderup, Mandy M T van Leent, et al.
Iscience|April 3, 2025
Targeting mTOR in myeloid cells prevents infection-associated inflammationYohana C Toner, Jazz Munitz, Geoffrey Prevot, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
Cell Reports|January 21, 2015
The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol BalanceManya Warrier, Diana M Shih, Amy C Burrows, et al.
Nature Biomedical Engineering|April 3, 2019
Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primatesMarnix Lameijer, Tina Binderup, Mandy M T van Leent, et al.
Nature Biomedical Engineering|April 25, 2019
Author Correction: Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primatesMarnix Lameijer, Tina Binderup, Mandy M T van Leent, et al.
Iscience|April 3, 2025
Targeting mTOR in myeloid cells prevents infection-associated inflammationYohana C Toner, Jazz Munitz, Geoffrey Prevot, et al.
Pageof 6